DexCom, Inc. (DXCM) EV/Sales Ratio: 6.18x
Is DexCom, Inc.’s EV/Sales ratio high or low?
DexCom, Inc.'s EV/Sales ratio of 6.18x is 55% below its 5-year average of 13.87x, near the low end of its 5-year range (4.78x–30.40x).
As of Thursday, June 11, 2026. 6.85% below its 12-month average of 6.63x.
DXCM EV/Sales Ratio Chart
DXCM Average EV/Sales Ratio Chart
DXCM Current vs Average EV/Sales Ratio Chart
DXCM EV/Sales Ratio Metrics
EV/SALES RATIO
6.18x
EV/SALES RATIO AVG TTM
6.63x
EV/SALES RATIO AVG 3Y
10.22x
EV/SALES RATIO AVG 5Y
13.87x
EV/SALES RATIO AVG 10Y
13.95x
EV/SALES RATIO AVG 15Y
14.20x
EV/SALES RATIO AVG 20Y
146.45x
CURRENT VS TTM AVG
-6.85%
CURRENT VS 3Y AVG
-39.53%
CURRENT VS 5Y AVG
-55.46%
CURRENT VS 10Y AVG
-55.70%
CURRENT VS 15Y AVG
-56.47%
CURRENT VS 20Y AVG
-95.78%
DXCM Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $28.92B | 6.18x | 6.63x | 10.22x | 13.87x |
| Biogen Inc. (BIIB) | $28.94B | 3.26x | 2.79x | 3.30x | 3.58x |
| IQVIA Holdings Inc. (IQV) | $30.08B | 1.85x | 2.83x | 3.22x | 3.53x |
| Medline Inc. (MDLN) | $31.40B | 1.41x | 1.60x | 1.60x | 1.60x |
| Veeva Systems Inc. (VEEV) | $26.31B | 7.65x | 12.50x | 13.33x | 15.70x |
| Centene Corporation (CNC) | $32.26B | 0.14x | 0.11x | 0.20x | 0.29x |
| Zoetis Inc. (ZTS) | $34.27B | 4.40x | 6.71x | 8.77x | 9.90x |
| Waters Corporation (WAT) | $23.21B | 9.27x | 7.03x | 7.13x | 7.32x |
| United Therapeutics Corporation (UTHR) | $23.15B | 7.78x | 6.45x | 5.72x | 5.77x |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 6.13x | 7.35x | 7.51x | 8.18x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
DexCom, Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for DexCom, Inc. (DXCM)?
- The EV/Sales ratio for DXCM stock is 6.18x.
- Is DexCom, Inc.'s EV/Sales ratio high or low?
- DexCom, Inc.'s EV/Sales ratio of 6.18x is 55% below its 5-year average of 13.87x, near the low end of its 5-year range (4.78x–30.40x).
- What is the TTM average EV/Sales ratio for DexCom, Inc. (DXCM)?
- The TTM average EV/Sales ratio for DXCM stock is 6.63x.
- What is the 3Y average EV/Sales ratio for DexCom, Inc. (DXCM)?
- The 3Y average EV/Sales ratio for DXCM stock is 10.22x.
- What is the 5Y average EV/Sales ratio for DexCom, Inc. (DXCM)?
- The 5Y average EV/Sales ratio for DXCM stock is 13.87x.
- What is the 10Y average EV/Sales ratio for DexCom, Inc. (DXCM)?
- The 10Y average EV/Sales ratio for DXCM stock is 13.95x.
- What is the 15Y average EV/Sales ratio for DexCom, Inc. (DXCM)?
- The 15Y average EV/Sales ratio for DXCM stock is 14.20x.
- What is the 20Y average EV/Sales ratio for DexCom, Inc. (DXCM)?
- The 20Y average EV/Sales ratio for DXCM stock is 146.45x.
DexCom, Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-11 | 6.18x |
| 2026-06-10 | 6.16x |
| 2026-06-09 | 6.44x |
| 2026-06-08 | 6.31x |
| 2026-06-05 | 6.01x |
| 2026-06-04 | 5.99x |
| 2026-06-03 | 6.00x |
| 2026-06-02 | 6.06x |
| 2026-06-01 | 6.17x |
| 2026-05-29 | 6.08x |
| 2026-05-28 | 5.97x |
| 2026-05-27 | 5.80x |
| 2026-05-26 | 5.94x |
| 2026-05-22 | 5.95x |
| 2026-05-21 | 5.93x |
| 2026-05-20 | 5.89x |
| 2026-05-19 | 5.52x |
| 2026-05-18 | 5.37x |
| 2026-05-15 | 5.09x |
| 2026-05-14 | 4.78x |
| 2026-05-13 | 4.84x |
| 2026-05-12 | 5.05x |
| 2026-05-11 | 4.90x |
| 2026-05-08 | 5.01x |
| 2026-05-07 | 5.03x |
| 2026-05-06 | 4.99x |
| 2026-05-05 | 4.91x |
| 2026-05-04 | 4.96x |
| 2026-05-01 | 5.07x |
| 2026-04-30 | 4.92x |
| 2026-04-29 | 5.03x |
| 2026-04-28 | 5.18x |
| 2026-04-27 | 5.36x |
| 2026-04-24 | 5.37x |
| 2026-04-23 | 5.47x |
| 2026-04-22 | 5.53x |
| 2026-04-21 | 5.46x |
| 2026-04-20 | 5.63x |
| 2026-04-17 | 5.58x |
| 2026-04-16 | 5.34x |
| 2026-04-15 | 5.37x |
| 2026-04-14 | 5.49x |
| 2026-04-13 | 5.50x |
| 2026-04-10 | 5.58x |
| 2026-04-09 | 5.72x |
| 2026-04-08 | 5.73x |
| 2026-04-07 | 5.50x |
| 2026-04-06 | 5.51x |
| 2026-04-02 | 5.43x |
| 2026-04-01 | 5.44x |
| 2026-03-31 | 5.47x |
| 2026-03-30 | 5.40x |
| 2026-03-27 | 5.43x |
| 2026-03-26 | 5.76x |
| 2026-03-25 | 5.82x |
| 2026-03-24 | 5.80x |
| 2026-03-23 | 5.74x |
| 2026-03-20 | 5.83x |
| 2026-03-19 | 5.86x |
| 2026-03-18 | 5.89x |
| 2026-03-17 | 5.86x |
| 2026-03-16 | 5.78x |
| 2026-03-13 | 5.60x |
| 2026-03-12 | 5.69x |
| 2026-03-11 | 5.78x |
| 2026-03-10 | 5.90x |
| 2026-03-09 | 5.98x |
| 2026-03-06 | 5.93x |
| 2026-03-05 | 6.15x |
| 2026-03-04 | 6.34x |
| 2026-03-03 | 6.35x |
| 2026-03-02 | 6.41x |
| 2026-02-27 | 6.38x |
| 2026-02-26 | 6.47x |
| 2026-02-25 | 6.36x |
| 2026-02-24 | 6.36x |
| 2026-02-23 | 6.37x |
| 2026-02-20 | 6.35x |
| 2026-02-19 | 6.28x |
| 2026-02-18 | 6.33x |
| 2026-02-17 | 6.13x |
| 2026-02-13 | 6.09x |
| 2026-02-12 | 5.67x |
| 2026-02-11 | 6.31x |
| 2026-02-10 | 6.31x |
| 2026-02-09 | 6.49x |
| 2026-02-06 | 6.48x |
| 2026-02-05 | 6.47x |
| 2026-02-04 | 6.55x |
| 2026-02-03 | 6.63x |
| 2026-02-02 | 6.71x |
| 2026-01-30 | 6.75x |
| 2026-01-29 | 6.84x |
| 2026-01-28 | 6.78x |
| 2026-01-27 | 6.81x |
| 2026-01-26 | 6.78x |
| 2026-01-23 | 6.74x |
| 2026-01-22 | 6.83x |
| 2026-01-21 | 6.67x |
| 2026-01-20 | 6.54x |
| 2026-01-16 | 6.44x |
| 2026-01-15 | 6.41x |
| 2026-01-14 | 6.45x |
| 2026-01-13 | 6.50x |
| 2026-01-12 | 6.57x |
| 2026-01-09 | 6.24x |
| 2026-01-08 | 6.34x |
| 2026-01-07 | 6.49x |
| 2026-01-06 | 6.47x |
| 2026-01-05 | 6.27x |
| 2026-01-02 | 6.17x |
| 2025-12-31 | 6.15x |
| 2025-12-30 | 6.21x |
| 2025-12-29 | 6.25x |
| 2025-12-26 | 6.26x |
| 2025-12-24 | 6.25x |
| 2025-12-23 | 6.20x |
| 2025-12-22 | 6.25x |
| 2025-12-19 | 6.12x |
| 2025-12-18 | 6.11x |
| 2025-12-17 | 6.10x |
| 2025-12-16 | 6.15x |
| 2025-12-15 | 6.09x |
| 2025-12-12 | 6.20x |
| 2025-12-11 | 6.38x |
| 2025-12-10 | 6.26x |
| 2025-12-09 | 6.15x |
| 2025-12-08 | 6.08x |
| 2025-12-05 | 6.07x |
| 2025-12-04 | 6.05x |
| 2025-12-03 | 6.01x |
| 2025-12-02 | 5.98x |
| 2025-12-01 | 5.89x |
| 2025-11-28 | 5.89x |
| 2025-11-26 | 5.80x |
| 2025-11-25 | 5.73x |
| 2025-11-24 | 5.78x |
| 2025-11-21 | 5.60x |
| 2025-11-20 | 5.43x |
| 2025-11-19 | 5.55x |
| 2025-11-18 | 5.59x |
| 2025-11-17 | 5.44x |
| 2025-11-14 | 5.40x |
| 2025-11-13 | 5.55x |
| 2025-11-12 | 5.54x |
| 2025-11-11 | 5.41x |
| 2025-11-10 | 5.11x |
| 2025-11-07 | 5.13x |
| 2025-11-06 | 5.40x |
| 2025-11-05 | 5.51x |
| 2025-11-04 | 5.68x |
| 2025-11-03 | 5.62x |
| 2025-10-31 | 5.42x |
| 2025-10-30 | 6.32x |
| 2025-10-29 | 6.80x |
| 2025-10-28 | 6.90x |
| 2025-10-27 | 7.03x |
| 2025-10-24 | 7.01x |
| 2025-10-23 | 7.07x |
| 2025-10-22 | 7.04x |
| 2025-10-21 | 6.95x |
| 2025-10-20 | 6.83x |
| 2025-10-17 | 6.65x |
| 2025-10-16 | 6.63x |
| 2025-10-15 | 6.54x |
| 2025-10-14 | 6.61x |
| 2025-10-13 | 6.52x |
| 2025-10-10 | 6.51x |
| 2025-10-09 | 6.79x |
| 2025-10-08 | 6.76x |
| 2025-10-07 | 6.60x |
| 2025-10-06 | 6.63x |
| 2025-10-03 | 6.69x |
| 2025-10-02 | 6.64x |
| 2025-10-01 | 6.60x |
| 2025-09-30 | 6.72x |
| 2025-09-29 | 6.64x |
| 2025-09-26 | 6.70x |
| 2025-09-25 | 6.81x |
| 2025-09-24 | 6.74x |
| 2025-09-23 | 6.80x |
| 2025-09-22 | 6.93x |
| 2025-09-19 | 6.73x |
| 2025-09-18 | 7.52x |
| 2025-09-17 | 7.59x |
| 2025-09-16 | 7.60x |
| 2025-09-15 | 7.50x |
| 2025-09-12 | 7.56x |
| 2025-09-11 | 7.54x |
| 2025-09-10 | 7.54x |
| 2025-09-09 | 7.77x |
| 2025-09-08 | 7.73x |
| 2025-09-05 | 7.97x |
| 2025-09-04 | 8.00x |
| 2025-09-03 | 7.82x |
| 2025-09-02 | 7.38x |
| 2025-08-29 | 7.48x |
| 2025-08-28 | 7.46x |
| 2025-08-27 | 7.58x |
| 2025-08-26 | 7.55x |
| 2025-08-25 | 7.54x |
| 2025-08-22 | 8.14x |
| 2025-08-21 | 7.98x |
| 2025-08-20 | 8.08x |
| 2025-08-19 | 8.01x |
| 2025-08-18 | 8.00x |
| 2025-08-15 | 8.01x |
| 2025-08-14 | 7.92x |
| 2025-08-13 | 7.92x |
| 2025-08-12 | 7.94x |
| 2025-08-11 | 7.72x |
| 2025-08-08 | 7.82x |
| 2025-08-07 | 7.58x |
| 2025-08-06 | 7.58x |
| 2025-08-05 | 7.49x |
| 2025-08-04 | 7.57x |
| 2025-08-01 | 7.85x |
| 2025-07-31 | 8.00x |
| 2025-07-30 | 8.78x |
| 2025-07-29 | 9.18x |
| 2025-07-28 | 9.20x |
| 2025-07-25 | 9.15x |
| 2025-07-24 | 8.93x |
| 2025-07-23 | 8.90x |
| 2025-07-22 | 8.77x |
| 2025-07-21 | 8.66x |
| 2025-07-18 | 8.65x |
| 2025-07-17 | 8.67x |
| 2025-07-16 | 8.67x |
| 2025-07-15 | 8.73x |
| 2025-07-14 | 8.79x |
| 2025-07-11 | 8.59x |
| 2025-07-10 | 8.80x |
| 2025-07-09 | 8.74x |
| 2025-07-08 | 8.63x |
| 2025-07-07 | 8.55x |
| 2025-07-03 | 8.55x |
| 2025-07-02 | 8.62x |
| 2025-07-01 | 8.62x |
| 2025-06-30 | 8.98x |
| 2025-06-27 | 8.89x |
| 2025-06-26 | 8.76x |
| 2025-06-25 | 8.72x |
| 2025-06-24 | 9.01x |
| 2025-06-23 | 8.25x |
| 2025-06-20 | 8.26x |
| 2025-06-18 | 8.36x |
| 2025-06-17 | 8.44x |
| 2025-06-16 | 8.56x |
| 2025-06-13 | 8.46x |
| 2025-06-12 | 8.54x |
| 2025-06-11 | 8.56x |
| 2025-06-10 | 8.74x |
| 2025-06-09 | 8.82x |
| 2025-06-06 | 8.92x |
| 2025-06-05 | 8.83x |
| 2025-06-04 | 8.81x |
| 2025-06-03 | 8.93x |
| 2025-06-02 | 8.81x |
| 2025-05-30 | 8.83x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach